Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA.
J Urol. 2012 Jul;188(1):51-7. doi: 10.1016/j.juro.2012.03.006. Epub 2012 May 14.
The relative effectiveness of partial vs radical nephrectomy remains unclear in light of the recent phase 3 European Organization for the Research and Treatment of Cancer trial. We performed a systematic review and meta-analysis of partial vs radical nephrectomy for localized renal tumors, considering all cause and cancer specific mortality, and severe chronic kidney disease.
Cochrane Central Register of Controlled Trials, MEDLINE®, EMBASE®, Scopus and Web of Science® were searched for sporadic renal tumors that were surgically treated with partial or radical nephrectomy. Generic inverse variance with fixed effects models were used to determine the pooled HR for each outcome.
Data from 21, 21 and 9 studies were pooled for all cause and cancer specific mortality, and severe chronic kidney disease, respectively. Overall 31,729 (77%) and 9,281 patients (23%) underwent radical and partial nephrectomy, respectively. According to pooled estimates partial nephrectomy correlated with a 19% risk reduction in all cause mortality (HR 0.81, p < 0.0001), a 29% risk reduction in cancer specific mortality (HR 0.71, p = 0.0002) and a 61% risk reduction in severe chronic kidney disease (HR 0.39, p < 0.0001). However, the pooled estimate of cancer specific mortality for partial nephrectomy was limited by the lack of robustness in consistent findings on sensitivity and subgroup analyses.
Our findings suggest that partial nephrectomy confers a survival advantage and a lower risk of severe chronic kidney disease after surgery for localized renal tumors. However, the results should be evaluated in the context of the low quality of the existing evidence and the significant heterogeneity across studies. Future research should use higher quality evidence to clearly demonstrate that partial nephrectomy confers superior survival and renal function.
鉴于最近的欧洲癌症研究与治疗组织(EORTC)三期临床试验,部分肾切除术与根治性肾切除术的相对效果仍不明确。我们对局限性肾肿瘤的部分肾切除术与根治性肾切除术进行了系统评价和荟萃分析,同时考虑了全因死亡率和癌症特异性死亡率以及严重慢性肾脏病。
检索 Cochrane 对照试验中心注册库、MEDLINE、EMBASE、Scopus 和 Web of Science 以获取接受部分或根治性肾切除术治疗的散发性肾肿瘤的相关研究。使用通用倒数方差固定效应模型来确定每个结局的汇总 HR。
分别有 21、21 和 9 项研究的数据被汇总用于全因死亡率和癌症特异性死亡率以及严重慢性肾脏病的分析。总体上,31729 例(77%)和 9281 例(23%)患者分别接受了根治性和部分肾切除术。根据汇总估计,部分肾切除术与全因死亡率降低 19%相关(HR 0.81,p < 0.0001)、癌症特异性死亡率降低 29%相关(HR 0.71,p = 0.0002)以及严重慢性肾脏病降低 61%相关(HR 0.39,p < 0.0001)。然而,部分肾切除术的癌症特异性死亡率汇总估计受到敏感性和亚组分析结果不一致的缺乏稳健性的限制。
我们的研究结果表明,对于局限性肾肿瘤,部分肾切除术可带来生存获益并降低术后发生严重慢性肾脏病的风险。然而,鉴于现有证据质量较低且研究间存在显著异质性,这些结果应在具体背景下进行评估。未来的研究应使用更高质量的证据来明确表明部分肾切除术可带来更好的生存和肾功能。